✦ LIBER ✦

Preclinical and Phase 1 clinical characterization of CI-979/ RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease

✍ Scribed by Allen J. Sedman; Howard Bockbrader; Roy D. Schwarz

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trials with WAL 2014, a

✍ Waclaw S. Adamus; Joachim P. Leonard; Wolfgang Tröger 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 668 KB

M1 Agonists for the Treatment of Alzheim

✍ A. FISHER; E. HELDMAN; D. GURWITZ; R. HARING; Y. KARTON; H. MESHULAM; Z. PITTEL; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB

Preclinical and early clinical studies o

✍ Lavrovsky, Yan; Ivachtchenko, Alexander V.; Morozova, M.; Salimov, R.M.; Kasey, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Use of an M1/M4-selective muscarinic ago

✍ Hanson, Seth A.; Verdone, Melinda L.; Hendrickson, Michael L.; Ockuly, Jeffrey C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Preclinical characterization of RO460252

✍ Borroni, Edilio; Wyler, Rene; Messer, Juergen; Nave, Stephane; Cesura, Andrea 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Preclinical characterization of a select

✍ Bitner, Robert; Anderson, David; Drescher, Karla; Kohlhaas, Kathy; Gronlien, Hal 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 75 KB